We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has cleared a next-generation integrated ...
(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...
Please provide your email address to receive an email when new articles are posted on . The mean relative absolute difference between CGM and other glucose measurements in the hospital was less than ...
A 180-day implantable continuous glucose monitor (CGM) was found to be both safe and effective, according to the prospective PROMISE study. In an analysis of 181 adults with diabetes, Senseonics' next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback